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Abstract
Background: Secretory phospholipase A2 group IIA (sPLA2-IIA) has been identified as a biomarker of atherosclerosis in
observational and animal studies. The protein is encoded by the PLA2G2A gene and the aim of this study was to test the
functionality of two PLA2G2A non-coding SNPs, rs11573156 C.G and rs3767221 T.G where the rare alleles have been
previously associated with higher and lower sPLA2-IIA levels respectively.
Methodology/Principal Findings: Luciferase assays, electrophoretic mobility shift assays (EMSA), and RNA expression by RT-
PCR were used to examine allelic differences. For rs3767221 the G allele showed,55% lower luciferase activity compared to
the T allele (T = 62.1 (95% CI 59.1 to 65.1) G = 27.8 (95% CI 25.0 to 30.6), p = 1.22610235, and stronger EMSA binding of a
nuclear protein compared to the T-allele. For rs11573156 C .G there were no luciferase or EMSA allelic differences seen. In
lymphocyte cell RNA, from individuals of known rs11573156 genotype, there was no allelic RNA expression difference for
exons 5 and 6, but G allele carriers (n = 7) showed a trend to lower exon 1–2 expression compared to CC individuals. To take
this further, in the ASAP study (n = 223), an rs11573156 proxy (r2 = 0.91) showed ,25% higher liver expression of PLA2G2A
(1.67610217) associated with the G allele. However, considering exon specific expression, the association was greatly
reduced for exon 2 (4.561025) compared to exons 3–6 (10210 to 10220), suggesting rs11573156 G allele-specific exon 2
skipping.
Conclusion: Both SNPs are functional and provide useful tools for Mendelian Randomisation to determine whether the
relationship between sPLA2-IIA and coronary heart disease is causal.
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Introduction
Elevated levels of secretory phospholipases (sPLA2s) show
association with several diseases such as coronary heart disease
(CHD), rheumatoid arthritis and asthma [1–3]. Three sPLA2
enzymes have been identified with links to CHD; sPLA2-IIA
(NP_001076000.1), sPLA2-V (GenBank: AAX68682.1) and
sPLA2-X (NP_003552.1) [4]. SPLA2 enzymes act by hydrolysing
the sn-2 ester bond of phospholipids to release a lyso-phospholipid
and a non-esterified free fatty acid (NEFA). Release of the NEFA
arachidonic acid (AA) is a key step as a precursor in the production
of eicosanoids such as leukotrines, thromboxanes and prostaglan-
dins. It therefore promotes these pro-inflammatory lipid mediators
which aid the initiation and maintenance of prolonged inflamma-
tory responses in the body, and are implicated in the development
of atherosclerosis [5,6].
sPLA2 enzymes further contribute to atherogenesis by
hydrolysing the outer phospholipid layer of low density
lipoprotein (LDL) particles in the circulation, generating small-
dense LDL (sd-LDL) particles which can then transverse the
endothelial cell layer of the artery wall into the intima, where
they are further modified [7]. This modification increases the
propensity of the particles to aggregate and bind to proteogly-
cans, resulting in aggregation of sd-LDL in the intima. The
proinflammatory products released by the sPLA2 hydrolysis of
phospholipids stimulate monocytes to enter the intima via the
endothelial cell wall where they transform into macrophages and
take up small dense (sd)-LDL. This leads to foam cell formation
and increased atherosclerotic plaque size [7].
The role of sPLA2-IIA in atherogenesis is evident from animal
studies. C57BL/6 mice are a natural knockout model for sPLA2-
IIA expression. This makes these mice excellent transgenic models
for human sPLA2-IIA, as any recorded changes in atherosclerosis
attributed to sPLA2-IIA will be due to the human transgene since
there is no confounding by endogenous mouse sPLA2-IIA [8].
Mice transgenic for PLA2G2A develop atherosclerosis and when
macrophages from these mice are transplanted into atherosclero-
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sis-prone knockout mice, either low density receptor Ldlr2/2 or
Apolipoprotein E (Apoe) 2/2, atherosclerosis is enhanced
[9,10,11,12].
The observational studies in prospective cohorts and in the
setting of acute coronary syndrome patients support these findings,
with both higher sPLA2-IIA levels, and notably higher sPLA2
activity, showing significant association with risk of CAD [9–11].
SPLA2-IIA is the most abundantly expressed of the sPLA2
proteins [12], and is mainly expressed in the liver, where it is
secreted into the circulation, and in the arterial wall where further
modification of sd-LDL takes place.
We previously identified six tagging SNPs (tSNPs), capturing
92% of the variation of PLA2G2A (Chr1, NC_000001.10) [13].
These were genotyped in a cohort of patients with type 2 diabetes
and their association with sPLA2-IIA levels and lipid traits was
examined. Two tSNPs showed strong association with sPLA2-IIA
levels. Compared to individuals homozygous for the common C
allele for rs11573156 C.G (NC_000001.10:g20306146G.C) in
the 59UTR of PLA2G2A (Figure 1), the rare G homozygotes had
2.2 ng/ml higher sPLA2-IIA levels (p = 1.9610214). For the
second variant, rs3767221 T.G
(NC_000001.10:g20301781A.C) in the 39UTR (Figure 1), the
opposite effect was seen with the rare G homozygotes having
significantly lower (1.8 ng/ml) sPLA2-IIA levels (p = 2.5610210)
compared to the wild-type T carriers [13]. The ultimate aim of our
study was to identify a robust functional genetic variant which
could be used to determine if the relationship between high
sPLA2-IIA levels and coronary heart disease risk was causal or not,
a process termed Mendelian Randomization.
Results
Allele-specific Expression of PLA2G2A in Human Liver
To examine the potential allele-specific expression of PLA2G2A,
we analysed PLA2G2A expression data from the ASAP study.
Measurements of PLA2G2A mRNA expression were investigated
in the following tissues; liver, mammary arteries, dilated and non-
dilated ascending aorta and heart. PLA2G2A mRNA was shown to
be most significantly expressed in the aortic adventitia, liver and
heart (Figure 2). The most significant allele-specific differential
expression of PLA2G2A mRNA was found to be in the liver. The
SNP rs11573156 was not measured directly on the Illumina
Human 610W-Quad Beadarray, so the rs10732279 SNP (Figure 1)
was used as a proxy (r2 = 0.91 in Caucasian Europeans, HapMap).
This proxy SNP showed the greatest overall differential expression
of PLA2G2A and explained 29.3% of the variance in PLA2G2A
mRNA in the liver, suggesting that this SNP may have a functional
effect. The genotype effect of rs10732279 on PLA2G2A liver
mRNA is presented in Figure 3a; compared to the common A
homozygotes, carriers of the rare G allele had roughly 25% higher
expression of PLA2G2A (p = 1.67610217).
Rs3767221 was not covered on the array nor was there a strong
proxy for this SNP. However, using the 1000 genomes database
we were able to impute rs3767221 and these results predicted an
association of rs3767221 with PLA2G2A, albeit with less accuracy
than for rs11573156. The mach1 r2 value was shown to be 0.41.
When the differential values of PLA2G2A for this imputed SNP
were analysed they showed a significant association of
p = 3.661024 (this was weaker than that seen for rs10732279,
the proxy for rs11573156) with carriers of the common allele (T)
showing higher expression compared to samples homozygous for
the rare allele (G) (Figure 3b).
Rs3767221 T.G is Associated with Altered PLA2G2A
Promoter Activity
Results from the luciferase assays for rs3767221 T.G are
shown in Figure 4. A significant difference was seen, with the G
allele showing ,55% lower luciferase activity compared to the T
allele (T=62.1 (95% CI 59.1 to 65.1) G= 27.8 (95% CI 25.0 to
30.6), p = 1.22610235). An EMSA (Figure 5) confirmed differen-
tial binding of nuclear protein between the T and G alleles,
illustrated by the additional band seen with the biotin-labelled
rs3767221 G, compared to rs3767221 T. This additional band
seen with the G variant was competed out by the un-biotinylated
G probe, but not the non-specific Sp1 probe, suggesting specific
binding of a transcription factor in the presence of the G allele but
not the T allele. The difference in transcription factor binding
associated with this 39UTR SNP could influence the rate of
transcription and/or mRNA stability, thus affecting PLA2G2A
expression and levels of sPLA2-IIA.
To investigate this further, rs3767221 G samples were
competed with an unlabelled SREBP 1 consensus sequence. For
rs3767221 G, a distinct reduction in the intensity of the band was
seen, suggesting that SREBP 1 may be involved in the differential
binding to the alleles of rs3767221 (Figure 5).
Rs11573156 C.G is Associated with Alternative Splicing
of PLA2G2A
The luciferase assays for rs11573156 C and G alleles showed
very low transcription, being in the order of 1.2 to 1.6 relative
Figure 1. A map of the PLA2G2A gene (6 exon transcript). This map identifies rs11573156, rs10732279 and rs3767221 in the 59UTR, intronic and
39UTR, respectively. Translated exons are distinguished by hatching. Untranslated exons are unfilled. The gene is normally reverse transcribed.
doi:10.1371/journal.pone.0041139.g001
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luciferase units, compared to the promoter-less pGL3-Basic vector
alone, which provided a baseline measurement in the order of 1
relative luciferase unit. The G allele shows a modest 10% higher
level (C= 1.21 (95% CI 1.13 to 1.30), G= 1.36 (95% CI 1.27 to
1.46), p = 0.02 (Figure 6).
EMSAs for the rs11573156 C or G allele did not show any
specific nuclear protein binding (Figure 7). Additionally, the
transcription factor binding site prediction algorithm MatInspec-
tor did not identify any likely putative differential transcription
factor binding sites in the 200 bp region flanking rs11573156.
Examination of this region on the UCSC Genome Browser also
showed an absence of predicted transcription factor binding sites.
Semi-quantitative RT-PCR on lymphocyte cell cDNA samples
from individuals of known genotype, across PLA2G2A exons 1 and
2 showed a trend towards lower expression levels in the
rs11573156 CG and GG individuals, when compared to the 5
rs11573156 C homozygotes, the mean expression in the 7
combined rs11573156 CG and GG individuals showed a non-
significant trend towards lower expression of exon 1 and 2
(,4.9%, p= 0.10) in carriers of the G allele (Figure 8). For exons
Figure 2. Relative Expression of PLA2G2AmRNA in tissues from the ASAP study. This chart shows the relative expression of PLA2G2AmRNA
across 5 tissues; liver, aorta intima-media, aorta adventitia, mammary artery intima-media and heart, in 223 patients undergoing aortic valve surgery
in the Advanced Study of Aortic Pathology (ASAP) study.
doi:10.1371/journal.pone.0041139.g002
Figure 3. a. Differential PLA2G2A expression of rs10732279 in the Liver. Results from the Advanced Study of Aortic Pathology of the overall
differential liver expression of PLA2G2A according to rs10732279 (A.G) genotype. Rare G carriers have significantly higher PLA2G2A expression than
common A homozygotes (p = 1.67610217). b. Predicted Differential PLA2G2A expression of rs3767221 in the Liver. Results from the
Advanced Study of Aortic Pathology relative to the 1000 Genomes Project imputed SNPs for PLA2G2A. The figure shows the overall differential
expression predicted for rs3767221 (T.G) in the liver. Common T carriers have significantly higher PLA2G2A expression than rare G homozygotes
(p = 3.661024).
doi:10.1371/journal.pone.0041139.g003
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5–6, which are present in all six PLA2G2A transcripts, no genotype
effect on expression levels was seen (p = 0.54; Figure 8). These data
were all normalised to a common housekeeping gene, GAPDH.
These exon-specific gene expression assay results suggest that
PLA2G2A exon 1 or 2, but not exons 5 and 6, are differentially
expressed in a genotype-specific manner according to rs11573156.
In order to expand on these results, PLA2G2A expression was
analysed in the ASAP study.
The ASAP study expression array included a single probe set
from exon 2, and two probe sets for each of exons 3–6, and
Figure 9a shows the rs10732279 allele-specific expression for the
nine probes. Rs11573156 is located near the alternately spliced,
untranslated exon 2. Of the 6 different PLA2G2A transcripts
reported, only two are protein coding and only one contains the
alternatively spliced exon 2 (Ensemble Genome Browser)
(Figure 9b). While rs10732279 genotype did not strongly influence
the expression of exon 2, for all exons from exon 3 onwards
carriers of rs10732279 G had higher expression than rs10732279
A, consistent with the trend observed in the studies on primary
lymphocytes. The p-value for differential expression of exon 2
between the genotype groups was 4.561025 while that for the
other exons ranged from 10210 to 10220(Figure 9c). Compared
with exons 3–6 expression, the low exon 2 expression seen within
rs10732279 G carriers could suggest an absence of exon 2 in
rs10732279 G carriers.
We examined potential miRNA binding sites in exon 2, based
on the hypothesis that if there was a miRNA binding site in this
region, in the case of exon 2 being skipped control of gene
expression by the miRNA would be affected. According to the
analysis from PITA (Segal Lab of Computational Biology), there
was one putative miRNA binding site for miR-544 in the region
of exon 2, which was in position 96 and had low conservation
between species, making it a less likely functional candidate.
miRTar predicted 13 miRNAs binding to exon 2, with two of
them forming 8 mers and 11 of them 7 mer-m8. As expected
due to the use of the same criteria for the algorithms, all the 13
miRTar-predicted miRNAs were also predicted by RegRNA.
Furthermore, RegRNA predicted an additional 15 miRNAs
relevant to the exon 2 region. Therefore, based on results from
these algorithms there is the potential for miRNA binding to
affect PLA2G2A expression. This requires more detailed exam-
ination.
Discussion
We have previously reported that the PLA2G2A 59UTR SNP
rs11573156 and the 39UTR SNP rs3767221, are independently
associated with differences in levels of plasma sPLA2-IIA [13] and
here we show that both influence gene expression by acting
through different molecular mechanisms.
The difference in luciferase activity between the rs11573156 C
and G constructs is modest and of borderline statistical signifi-
cance, and the lack of mobility shift in the EMSA corroborated
our interpretation of the luciferase results that this SNP does not
lead to differential binding of a transcription factor. Rs11573156
lies in the region of exon 2. A clue that the genotype effect might
be acting through another mechanism came from the observation
that exon 2 is not always present in the reported transcripts of the
gene (NCBI Reference Sequences). When PLA2G2A expression
was tested in the limited samples of known genotype available to
us, we observed that, compared to expression of exons 5 and 6,
which showed no difference in expression by genotype, there was a
non-significant lower expression of exons 1 and 2 in G carriers
compared to C homozygotes. Our interest was to study the role of
sPLA2-IIA in CHD and tissues related to the vasculature; the
heart and the liver. Those tissues were available in the ASAP study
which provided the eQTLs for our analyses. The expression results
were confirmed by the results from the ASAP study which showed
that the SNP rs10732279, acting as proxy for rs11573156, was
associated with significantly lower differential expression of exon 2
compared to the following four exons of the gene, but significantly
increased total mRNA expression across all exons. We acknowl-
edge that the small number of samples and the high DCt values we
report here for the TaqMan gene expression results cannot act as
Figure 4. Luciferase Assay Activity Analysis Comparing rs3767221 T .G. The difference in luciferase activity (Relative Light Units) between
the T and G alleles of rs3767221 (forward orientation), normalised to pGL3 expression vector. Rs3767221 G (rare) shows a 55% lower Luc activity
compared to the T allele (wild type) and is compared to the promoter-free vector pGL3-Basic for baseline reference.
doi:10.1371/journal.pone.0041139.g004
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proof of this exon 2 skipping theory alone. However, taken
together with the ASAP study, these results implied that, in the
presence of the rare G allele, exon 2 was expressed less well,
suggesting that it was preferentially skipped.
Considering the very low levels of luciferase activity (there was
no significant increase in activity for either the C allele or the G
allele compared to the measure of activity from the promoter free
pGL3-Basic) in the luciferase experiment, it is likely that a negative
regulatory element exists in the region of exon 2 in the 59UTR.
Fan et al, using deletion mapping of the PLA2G2A promoter in
reporter gene assays, identified a negative element in the region -
1969 to -1624, which incorporates exon 2 (Ensembl Genome
Browser). When deleted from the full transcript, reporter gene
expression increased by ,400% [14].
Rs10732279, which showed the most significant association
with PLA2G2A expression in the ASAP study, is intronic and is not
in close proximity to any known functional sites (UCSC Genome
Browser). However our SNP of interest, rs11573156, for which it
acted as a proxy, is in very close proximity (37 bp) to a known
exon skipping site (beginning at chr1:20306884). One explanation
for why skipping of this exon leads to higher expression is the
possibility that it harbours a miRNA binding site. MiRNAs are
short, non-coding RNA sequences that bind to and interact with
mRNA targets in order to post-transcriptionally regulate gene
expression. MiRNA target seed sites are thought to occur most
frequently in the 39UTR. However, there is also evidence that they
can bind 59UTR sites and regulate them post-transcriptionally
[15,16]. Although there are fewer prediction algorithms available
Figure 5. EMSA Analysis of Potential Differential SREBP1 Binding Site for rs3767221 Variants. EMSA image for rs3767221; Lane 1: SREBP
1 specific binding as a positive control. Lane 2 shows the SREBP1 specific bands competed out by unlabelled SREBP1 consensus sequence. Lane 3 and
4 represent rs3767221 T (wild) with (Lane 4) and without (Lane 3) unlabelled competitor with non-specific binding. Lane 5 shows rs3767221 G (rare)
appears to have specific binding compared to the wild-type T. Specificity is confirmed in Lane 6 where the band is competed out with an unlabelled
rs3767221 G competitor. This confirms differential binding between T and G alleles. Lane 7 shows rs3767221 G competed with unlabelled SREBP 1
and the rs3767221 G specific band is less intense, suggesting SREBP 1 or a related transcription factor may bind at rs3767221 G. Lane 8 shows that the
specific band seen with the G allele does not show a loss of intensity with the non-specific competitor Sp1.
doi:10.1371/journal.pone.0041139.g005
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which include 59UTRs in their analysis, we have used PITA,
miRTar and RegRNA to examine the exon 2 region of PLA2G2A,
including the rs11573156 site. Using the above sites, which
provided overlapping data to a certain extent, we were able to
identify potential miRNA binding sites. Absence of the active
miRNA binding site, in the case of exon skipping, could account
for the loss of post-transcriptional repression.
To examine the possibility that rs11573156 is only marking the
true functional SNP in linkage disequilibrium, the LD between
rs11573156 and all known exon-boundary SNPs was examined
using the 1000 Genomes data and the SNAP Pairwise LD
program. There was no other genotyped variant at those positions
showing LD with rs11573156 above an r2 threshold of 0.7 paired.
There is strong evidence to suggest that rs3767221 T.G in the
39UTR of PLA2G2A is also functional. In this instance we have
shown that this is likely to be due to differential transcription factor
binding between the wild type and rare variant, with a binding site
created by the presence of the rare G allele. The migration of a
specific band seen with rs3767221 G corresponded to that of the
SREBP 1 positive control, used for all EMSA work. Competition
of the G allele with SREBP 1 unlabelled consensus sequence
resulted in lower intensity of the specific band, which was not seen
with the competition of the G allele with the non-specific Sp1
probe. However, we were unable to confirm SREBP 1 binding
using a supershift assay. Future work including a supershift assay
and EMSAs of nuclear extracts from cells of known genotype
could enhance these results. Prediction by MatInspector suggests a
potential cAMP binding protein site in the region of rs3767221 G
that is not predicted for rs3767221 T and cAMP is known to effect
human sterol regulation, including SREBP 1 binding [17] and to
play a role in sPLA2-IIA transcription regulation [18]. The UCSC
Genome Browser identifies a dense potential transcription factor
binding region in the sequence around rs3767221, which included
SREBP 1 or sPLA2 interacting transcription factors such as p300
[19,20] and LXR alpha [21]. Further experiments are needed to
verify and identify the transcription factor binding to this site. Both
MatInspector and the UCSC Genome Browser report several
other known transcription factor binding regions binding to this
site in addition to SREBP 1, including; RXRA, CEBPB, HNF4A
and p300, and the Aryl hydrocarbon receptor (AHR).
Observational studies show higher sPLA2-IIA levels associated
with the T variant and this is concordant with the higher luciferase
activity of the T allele and the higher PLA2G2A expression
associated with T allele carriers predicted by the ASAP study, so
we predict that the transcription factor binding to this region in G
allele carriers would act as a repressor.
Conclusions
The major aim of our study was to determine the functionality
of these two SNPs, with a view to validate their use as robust
genetic instruments to be used in Mendelian Randomization (MR)
analysis. The MR approach uses a genetic variant to validate the
causal relationship between a biomarker and outcome, in this case
sPLA2-IIA and CHD, by examining the relationship of the SNP
with both biomarker and outcome and testing the concordance of
effects [22]. We therefore conclude that these two functional
variants would be suitable, robust instruments to determine
whether sPLA2-IIA is causal of CHD using MR.
Materials and Methods
Plasmids and Site Directed Mutagenesis
A 2.27 Kb fragment upstream of the PLA2G2A translation start
site (GRCh37.p5, chr1:20,305,406 to 20,307,676) (Ensembl
Genome Browser), including wild-type rs11573156 C and the
predicted promoter sequence, was amplified from a DNA sample
of an individual homozygous for the C allele. The primers were as
follows:
Forward, 59 CCCC GCTAGCTGATCTCTGCCTT-
CATCTTTGTATG.
Reverse, 59CCCC AAGCTTCTGCTGGGTGGTCT-
CAACTTC.
The PCR conditions were; 95uC for 1 minute, then 30 cycles of
95uC for 1 minute, 68uC for 1 minute and 72uC for 1 minute,
Figure 6. Luciferase Assay Activity Analysis Comparing rs11573156 C.G. The difference in luciferase activity (Relative Light Units) between
the C and G alleles of rs11573156 normalised to pGL3-Basic. There is no pre-existing promoter in this vector and both inserted constructs for C and G
variants give very low levels of luciferase when compared with pGL3-Basic for baseline reference.
doi:10.1371/journal.pone.0041139.g006
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ending with 72uC for 5 minutes. The amplified fragment was
ligated into the pGL3-basic vector upstream of the Luciferase (Luc)
gene, using the HindIII and NheI restriction sites. Site directed
mutagenesis (Stratagene) was used to introduce the rs11573156 G
allele.
For rs3767221 T.G, a 303 bp fragment downstream of the
PLA2G2A protein coding sequence (GRCh37.p5, chr1:20,301,598
to 20,301,873) (Ensembl Genome Browser) was amplified using
the primers:
Forward 59CGCGGATCCCATGCAGGAGGCAC-
CAGTGTTATCTC.
Reverse 59ACGCGTCGACGCATGAGAACAAACAGGGG-
TAGGGG from an individual homozygous for the wild-type allele
(T). In this instance the rare G variant construct was created by
amplifying a DNA sample from individuals homozygous for the
rare variant (G). The PCR conditions were; 98uC for 2 minutes,
then 30 cycles of 98uC for 15 seconds, 62uC for 15 seconds and
72uC for 1 minute, ending with 72uC for 5 minutes. PCR
fragments were ligated into a pGL3-Promoter expression vector
(Promega UK), downstream of the Luc gene, using the BamHI and
SalI restriction sites. Constructs were transformed into DH5a
competent E.coli. All products were sequenced by Source
BioScience (London, UK) for sequence confirmation.
Dual Reporter Luciferase Assay
Luciferase activity was measured using the Dual Luciferase
Reporter Assay system (TM040, Promega, UK). Huh7 cells
(Health Protection Agency Culture Collections) (46104 cells/well
in a 96 well plate format) were transiently transfected with 200 ng
of the appropriate plasmid or control vector, 1 ng of pRL-TK co-
transfector (Promega, UK), and 0.02 mg Lipofectamine 2000
transfection reagent (Invitrogen) in serum free Opti-Mem serum
(Sigma). The cells were lysed 48 h after transfection. Results
represent the mean of 3 experiments, each performed in sets of 8
Figure 7. EMSA Analysis of Potential Differential Binding for rs11573156 C and G Variants. EMSA image of rs11573156 C and G alleles
showing no transcription factor binding. Lane 1 is SREBP 1 positive control that shows specific bands that are competed out with an unlabelled
SREBP 1 consensus sequence in lane 2. Lanes 3 and 4 show rs11573156 C (wild type) labelled and competed with unlabelled C competitor
respectively. There is no specific binding. Lanes 5 and 6 represent rs11573156 G (rare) labelled and competed with unlabelled G competitor
respectively, again with no specific binding. Lane 7 represents a second positive control with Sp1 specific binding and in Lane 8, labelled Sp1 with
unlabelled Sp1 competitor that competes out Sp1 specific bands.
doi:10.1371/journal.pone.0041139.g007
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repeats per sample, per plate. All kits and solutions were used as
per the manufacturers’ instructions.
Modified Nuclear Extraction Process
A t-175 flask of Huh7 cells was grown to 100% confluency. The
cells were washed with 20 ml of 16PBS and trypsinised after
which, serum-containing medium was added and the cells formed
a pellet when centrifuged at 1000 rpm for 5 minutes at 4uC and
the supernatant discarded.
The pellet was re-suspended in 5 ml ice-cold buffer A (1 ml 10 M
HEPES, pH 7.9; 150 ml 1.5 mM MgCl2; 500 ml 10 mMKCl) with
added 50 ml of 1006protease inhibitor (Pierce, PERBIO, Protease
Inhibitor Cocktail Kit) and incubated on ice for 10 minutes. The
cells were then centrifuged for 5 minutes 1000 rpm. The
supernatant was discarded. The pellet was re-suspended in 2 ml
Buffer A with 20 ml 1006 protease inhibitor and vortexed for 30
seconds. The re-suspended pellet mix was centrifuged for 2 minutes
at 13,000 rpm. The supernatant was discarded. The pellet was then
re-suspended in 400 ml Buffer C (2 ml 20 mM HEPES, pH 7.9;
50 mls 25% v/v glycerol; 10.5 ml 0.42 M NaCl; 150 ml
1.5 mM MgCl2; 40 ml 0.2 mM EDTA) and combined with 16 ml
of 1006protease inhibitor. This mix was vortexed for 1 minute and
incubated on ice for 10 minutes four times. The mix was centrifuged
at 13,000 rpm and 4uC for 50 minutes and the supernatant was
aliquotted into 50 ml volumes and stored at 280uC.
Chemiluminescent Electrophoretic Mobility Shift Assay
(Chemiluminescent EMSA)
Nuclear extracts were obtained from unstimulated Huh7 cells as
described above. Multiple nuclear extracts were tested for the
analysis of each SNP. An SREBP 1 probe and SREBP 1
unlabelled competitor were used as controls in each EMSA. An
Sp1 unlabelled competitor was used as a non-specific competitor
for rs3767221 G EMSAs and labelled and unlabelled Sp1 were
used as a secondary control for rs11573156 EMSAs. The
consensus sequence for the probes used for SREBP 1 and Sp1
have been detailed previously [23].
The probes used for the EMSAs are detailed below.
For rs11573156 C.G:
Forward wild type 59-AACCTCCCAGAGGGAGCAGC-
TATTTAAGGGGAG-39.
Reverse wild type 59-CTCCCCTTAAA-
TAGCTGCTCCCTCTGGGAGGTT-39.
Forward rare variant 59-AACCTCCCAGAGGGAGGAGC-
TATTTAAGGGGAG-39.
Reverse rare variant 59-CTCCCCTTAAA-
TAGCTCCTCCCTCTGGGAGGTT-39.
For rs3767221 T.G:
Forward wild type 59-TGAGCTCAAGCAATCATTG-
CACTTCAGCCT-39.
Reverse wild type 59-AGGCTGAAGTGCAATGATTGCTT-
GAGCTCA-39.
Forward rare variant 59-TGAGCTCAAGCAATCCTTG-
CACTTCAGCCT -39.
Reverse rare variant 59-AGGCTGAAGTGCAAG-
GATTGCTTGAGCTCA -39.
For SREBP 1:
SREBP1_F 59-TTTGAAAATCACCCCATGCAAACTC-39
SREBP1_R 59-GAGTTTGCATGGGGTGATTTTCAAA-39
For Sp1:
Sp1_F 59-ATTCGATCGGGGCGGGGCGAGC-39
Sp1_R 59-GCTCGCCCCGCCCCGATCGAAT-39
Probes were labelled using the Biotin 39-End DNA Labelling Kit
(Pierce, USA), as described by the manufacturer, and annealed to
the complementary labelled oligonucleotide. Each EMSA binding
Figure 8. TaqMan Gene Expression Analysis for rs11573156 C and G. TaqMan gene expression assay results for rs11573156 C vs. rs11573156
G expression levels across PLA2G2A exon 1–2 and exon 5–6. The X axis scale represents DCt, the number of amplification cycles required to reach a
pre-determined threshold of fluorescent signal. All samples were normalised to the housekeeping gene GAPDH.
doi:10.1371/journal.pone.0041139.g008
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reaction consisted of 2 ml of 106 binding buffer (100 mM Tris,
500 mM KCl; pH 7.5), 1 mg p [dI–dC]), 200 fmol biotin-labelled
DNA, and made to a total of 20 ml with dH2O, and incubated at
25uC for 30 min. Competition reactions were carried out with
30 min incubation on ice, prior to addition of labelled probes, using
1006unlabelled competitor DNA. Samples were loaded on to a 6%
polyacrylamide gel with 56 loading buffer, and electrophoresis was
carried out in 0.56TBE for 5 hours at 120 V at +4uC. The gel was
transferred to Hybond nylon membrane (Fermentas) by Southern
blot analysis overnight. The membrane was cross-linked using a UV
Figure 9. a. ASAP PLA2G2A Expression Analysis for Different rs10732279 Genotypes. Results from the ASAP study; liver expression levels
of exon-specific PLA2G2A probe sets stratified by rs10732279 genotype. PLA2G2A is covered by 9 exon-specific probe sets (1 in exon 2, and two each
in exon 3–6) b. The Known Protein Coding Transcripts for PLA2G2A. Known transcribed PLA2G2A transcripts showing alternate exon 2 skipping
from the UCSC Genome Browser (UCSC Genome Browser). c. PLA2G2A Exon-Specific Expression in the Liver. Results from the ASAP study; Liver
expression association between exon-specific PLA2G2A probe sets according to rs10732279 genotype. The y-axis give the –log10 (p-value) for the
PLA2G2A association for rs10732279, using an additive model. These values relate to the exon specific absolute expression levels shown in Figure 9a.
doi:10.1371/journal.pone.0041139.g009
Functional Analysis of Two PLA2G2A Variants
PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e41139
radiation. Protein/DNA complexes are identified with the addition
of the biotin label conjugate, horseradish peroxidase using the
Chemiluminescent Nucleic Acid Detection Module (Pierce, USA)
and visualised on CL-xposure X-ray film.
TaqMan Gene Expression
The effects of rs11573156 C.G on gene expression was
assessed using a TaqMan gene expression assay in a set of 12
healthy Caucasian laboratory volunteers, who had all given
informed consent: 5 samples were homozygous for the common
allele (CC), there were 4 heterozygous samples (CG) and the
frequency of homozygosity of the minor G allele (0.0625) meant it
was only possible to identify three GG homozygous samples from
our volunteer cohort. The samples were previously genotyped
using the TaqMan Genotyping protocol and analysed using the
relative quantitation (using comparative Ct) program on the ABI
Prism 7900 HT TaqMan machine. Lymphocytes were isolated
from 12 samples of 10 ml whole blood (Lymphocyte preparation
solution provided by PAA: The Cell Culture Company). RNA
was extracted from the isolated cells using the RNeasy Kit
(Qiagen). RNA samples were reverse transcribed using Super-
script III (Invitrogen). Two TaqMan ABI inventoried gene
expression assays, Hs01044022_m1, spanning human PLA2G2A
exon 1 and 2 and Hs00179898_m1, which spans exon 5 and 6
were used and compared to the housekeeping gene
Hs99999905_m1; GAPDH, (Applied Biosystems (ABI), California,
USA). In all instances the housekeeping gene showed no
difference in expression levels across all samples. Each sample
was run in triplicate for each assay on the ABI Prism 7900 HT
Real Time PCR System. Results were analysed using the REST-
384 Version 2 tool.
The RT-PCR conditions were as follows: For 20 ml reaction
volumes, 95uC for 2 minutes then, 40 cycles of 95uC for 1 second
and 60uC for 20 seconds.
Advanced Study of Aortic Pathology (ASAP) and
Evaluation of the Effects of PLA2G2A SNPs on PLA2G2A
mRNA Expression
The Advanced Study of Aortic Pathology (ASAP) recruited 223
patients undergoing aortic valve surgery at the Karolinska
University Hospital, Stockholm Sweden [24]. Biobank materials
for the ASAP study were generated after informed consent from
all participants had been obtained according to the declaration of
Helsinki and with approval by the ethics committee of the
Karolinska Institute (application numbers 02 to 147 and 2006/
784 to 31/1). Tissue biopsies were taken from liver, mammary
artery intima-media and dilated and non-dilated ascending aorta
intima-media and aorta adventitia and heart during surgery. The
medial and adventitial layers of the vascular specimen were
isolated by adventicectomy, and incubated with RNAlater
(Ambion, Austin, Texas, USA) and homogenised for mRNA
extraction as previously detailed [24]. Affymetrix Gene Chip
Human Exon 1.0 ST expression arrays were used. MRNA
expression was evaluated using RNA pre-processing as previously
described [24]. Participants were genotyped using the Illumina
Human 610W-Quad Bead array [24], which included 101 SNPs
in the region 200 kb up and downstream from the PLA2G2A
locus. Imputation of SNPs not covered by the Illumina Human
610W-Quad Bead array were imputed for the 1000 genome
project. Classification by mach1 suggests .0.3 as the lowest
threshold for r2. In our set this corresponded to ,10% mistakes.
Sequence Analysis of rs11573156 C.G and rs3767221
T.G
Prediction of transcription factor binding. Several tools
were used to examine the potential functional regions around the
two SNPs under investigation. MatInspector is a tool that runs
through specified FASTA sequences and was used to identify
potential transcription factor (TF) binding sites at and near the
two SNP locations. The UCSC Genome Bioinformatics Browser
stores information on known genes and their variants as well as
identified and suggested transcription factor binding sites, open
chromatin regions and known alternate splicing regions. We used
these tools, in addition, to check the other identified tSNPs to
examine if they might influence functional domains, but these
results were negative and we did not continue to investigate them
further.
Prediction of microRNA (miRNA) binding. In order to
predict potential microRNA (miRNA) binding sites in the 59UTR
we input the mRNA sequence for PLA2G2A, NM_000300 into
three genome-wide target prediction algorithms that focus outside
of the 39UTR. Using the first algorithm, the Probability of
Interaction by Target Accessibility (PITA), we searched for
possible microRNA targets (among 470 human microRNAs) that
form 8 mers with Exon 2. In the miRTar algorithm we searched
1,104 miRNAs across the selected region. The parameters
included information such as minimum free energy of hybrid-
ization between microRNAs and their predicted target site (MFE
of ,14 Kcal/mol) and an alignment score of $140 based on
structural information on the putative hybrid. The third
algorithm, RegRNA, identifies miRNA target sites against an
input mRNA sequence, which was the RefSeq mRNA ID
NM_00300 in our case. As before, we used as cut-off points
MFEs ,14 Kcal/mol and an alignment score of $140 which are
estimated from the miRanda algorithm.
Statistical Analysis
Statistical analysis of luciferase and TaqMan assays was
performed using SPSS version 12.0.1 (SPSS, Chicago, IL) and
an independent sample T-test was run to determine the p-value,
with a threshold of p,0.05. Statistical analysis of microarray
expression data was performed using R 2.13.0. P-values are
calculated using a linear additive model encoding genotypes
numerically. Plotting of location dependent associations in figure 9
was performed using the GeneRegionScan version 1.8.0 [25].
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